| Document |
Document Title |
|
WO/2015/181116A1 |
A process for preparing compounds of formula (I), or a salt, solvate or stereoisomer thereof, including Fulvestrant, which process comprises free radical to a compound of formula (III), or a salt, solvate or stereoisomer thereof. The inv...
|
|
WO/2015/135061A1 |
Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low DHEA ...
|
|
WO/2015/098152A1 |
The present invention is a method that is for preparing a crystallography sample for determining the molecular structure of a metabolite and that is characterized by having a step in which, by means of contacting, to a solvent solution c...
|
|
WO/2015/092647A1 |
The present invention relates to a new stereoselective process for the synthesis of 17(α)-17-acetyl-17-hydroxy-estr-4-en-3-one of formula (I), as well as to the new intermediates of the process. The 17(α)-17-acetyl-17-hy droxy-estr-4-e...
|
|
WO/2015/081827A1 |
Disclosed is a method for synthesizing a α-aryl, heteroaryl or alkenyl-α,α-2-fluoro allyl structure by palladium catalysis. Specifically, in the method of the present invention, a compound of formula A and a compound of formula B synt...
|
|
WO/2015/064479A1 |
A levonorgestrel crystal mixture comprising polymorphic levonorgestrel crystals α which give an X-ray powder diffraction spectrum that has diffraction peaks at the following diffraction angles (α) in terms of 2θ and polymorphic levono...
|
|
WO/2015/040051A1 |
The invention relates to a process for obtaining Estetrol or a salt or solvate thereof, the process comprising: a) reacting a compound of formula (IV) or a salt or solvate thereof, wherein R1 is a hydroxyl protecting group selected from ...
|
|
WO/2015/018596A1 |
The invention relates to a method and a kit for colouring keratinous fibers especially human hair. The invention more particularly relates to generating black coloured hair while minimising the off odour generated when a conventional pen...
|
|
WO/2015/006691A1 |
Various prodrug compounds having the general structure: Active agent- (acid)-(linker) - SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
|
|
WO/2014/175303A1 |
Provided are a new crystalline form of levonorgestrel, which is useful as an emergency contraception, etc., a manufacturing method for the same, and a drug composition. The powder X-ray diffraction spectrum of this β crystalline polym...
|
|
WO/2014/175302A1 |
Provided are a new form of levonorgestrel, which is useful as an emergency contraception, etc., a solid dispersion of levonorgestrel, a manufacturing method for the same, and a drug composition. The differential scanning calorimetry sp...
|
|
WO/2014/175304A1 |
Provided are a new crystalline form of levonorgestrel, which is useful as an emergency contraception, etc., a manufacturing method for the same, and a drug composition. The powder X-ray diffraction spectrum of this β crystalline polym...
|
|
WO/2014/169462A1 |
The present invention provides a class of fulvestrant ester derivatives and a preparation method thereof. Such a compound is an aliphatic ester compound formed by esterifying the -OH on positions C-3 and C-17 of the fulvestrant, having a...
|
|
WO/2014/162230A1 |
The present invention provides a process for the purification of norethindrone (I) from a mixture of dimethylformamide (DMF) and water. The invention further provides two processes for the purification of norethindrone acetate (II) from ...
|
|
WO/2014/154179A1 |
The present invention discloses compound 2β,3α,5α-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.
|
|
WO/2014/127201A1 |
The present disclosure is generally directed to neuroactive enantiomeric 15-, 16- and 17- substituted steroids with additional optional substituents at carbons 3, 4, 6, 7, 10 and 13, and pharmaceutically acceptable salts thereof, for use...
|
|
WO/2014/100228A1 |
The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorde...
|
|
WO/2014/091158A1 |
The present invention relates to testosterone derivatives of formula (I): in which n is an integer between 1 and 10 and Y is an activated or ready-to-be-activated group which enables the formation of an amide bond with a primary amine of...
|
|
WO/2014/075978A1 |
The present invention relates to a process for making abiraterone-3-acetate of formula (1) starting from dehydroepiandrosterone-3-acetate of formula (2) by converting it into the triflate of formula (5) in an inert solvent in the presenc...
|
|
WO/2014/057957A1 |
Provided are: a novel steroid compound useful for a diagnostic medicine; and a medicine comprising the steroid compound. A steroid compound represented by formula (1) (wherein R1 represents a hydroxy group, a sulfonyloxy-type protected h...
|
|
WO/2014/037873A1 |
There is described a process for the industrial synthesis of 11-methylene-18- methyl-estr-4-en-3, 17-dione, a compound having the structure formula (I) depicted below: (Formula I) (I) useful as intermediate compound in the synthesis of t...
|
|
WO/2013/131305A1 |
Disclosed are four compounds of crystal form of androsta-3β,5α,6β-triol (YC-6 for short) (YC-6 of A crystal form, YC-6 of B crystal form, YC-6 of C crystal form, YC-6 of D crystal form) and a method for preparing same. The four compou...
|
|
WO/2013/035943A1 |
The present invention relates to betulinic acid exhibiting anti-aging activity, wherein the betulinic acid according to the invention, functional foods containing the betulinic acid, or a pharmaceutical composition containing the betulin...
|
|
WO/2013/016725A1 |
Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.
|
|
WO/2012/164096A1 |
The present invention relates to a process for the preparation of a compound of formula (I) said process comprising the steps of : a) reacting a compound of formula (II), with an acylating or a silylating agent to produce a compound of f...
|
|
WO/2012/142687A1 |
The present invention can be used as an antitumour drug for testosterone-dependent tumours, in particular prostate cancer. The invention relates to a molecular compound composed of testosterone molecules chemically bonded to a chemothera...
|
|
WO/2012/131286A1 |
The present invention provides electrophilic alkylating reagents of formula II, wherein is an aryl group, R2 is an alkyl group, R3 is a substituted phenyl group, wherein the number of substituents (n) is greater than 2 and R4 is an anion...
|
|
WO/2012/129673A1 |
The present application discloses 17β hydroxy steroid dehydrogenase (17β HSD) type 1, 3, 10 inhibitors and use thereof (alone and in combination) in the treatment of cancer and other afflictions. 17β HSDl inhibitors include estradiol ...
|
|
WO/2012/134446A1 |
Disclosed herein are epiandrosterone and androsterone derivatives of Formula (II), process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2012/123324A1 |
The present invention relates to novel androstan derivatives, methods for their production, and their use for influencing plant growth.
|
|
WO/2012/110947A1 |
The present invention provides an improved process for preparation of levonorgestrel (3) which comprises of hydrolysis of 13 β-ethyl-3-methoxy-17α-ethynyl-gona-2,5(10)-dien-17β- o1 (2) with an acid in aprotic solvent. The present inve...
|
|
WO/2012/106514A2 |
This invention relates to a low cost rapid response diagnostic system to determine Cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG ...
|
|
WO/2012/083201A1 |
The invention relates to solid state forms of androst-5-ene-3α,7β,16α,17β- tetrol, formulations containing or prepared from such solid state forms and use of these materials for modulating unwanted inflammation including acute and ch...
|
|
WO/2012/059803A1 |
The present invention relates to the process for the preparation of estradiol valerate (I) which involves isolation of crystalline estradiol divalerate (III) by crystallization from an alcoholic solvent.
|
|
WO/2012/037261A2 |
Disclosed herein are 6-substituted 13-demethyl- estradiol derivatives as selective ERβ agonists. Also disclosed is a method for treating pain by administering these 6-substituted 13-demethyl-estradiol derivatives.
|
|
WO/2012/032529A1 |
The present invention provides methods for 1, 2-asymmetric reduction of other compounds wherein 1,2- trans diol is present. In particular the present invention discloses preparation of 17β-Estriol and its derivatives having substantiall...
|
|
WO/2012/013816A1 |
The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia.
|
|
WO/2012/011106A1 |
The present invention provides an improved process for the preparation of 17-desoxy corticosteroid derivatives in a single chemical step by reacting the 17-hydroxy starting material with an excess of Trimethylsilyl Iodide. The present in...
|
|
WO/2011/138460A1 |
The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.
|
|
WO/2011/127232A2 |
The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds ...
|
|
WO/2011/114220A1 |
Isolated compounds from adelostemma gracillimum refined fractions and compositions containing the compounds are provided by the present invention. Adelostemma gracillimum refined fractions and the extraction process thereof are also prov...
|
|
WO/2011/108661A1 |
Disclosed is a method for producing a silylenol ether compound, which is simple, has broad utility, and has a low environmental load (produces little waste). Specifically disclosed is a method for producing a silylenol ether compound (3)...
|
|
WO/2011/098439A2 |
The invention relates to a process for the preparation of a compound of formula (I): wherein R1 and R2 are as defined in the description, by reaction of a compound of formula (II) with a base. Compound (I) is an intermediate useful in th...
|
|
WO/2011/066542A2 |
Disclosed are compounds of the formula (I): where in R1, R2, R3 and R4 are independent l y hydrogen, C1 -C6 alkyl, halo, a sulfate, a glucuronide, -OH, a bulky group, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, N ( CH2 ) n; a phospha...
|
|
WO/2011/009529A2 |
The invention relates to a 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11methylene
oxyalkylene aryl derivative of formula (I) exhibiting progesterone-antagonistic effects and to methods for the production thereof, to the use thereo...
|
|
WO/2010/096928A1 |
Methods and devices for liquid-liquid extraction using digital microfluidic arrays are provided. A polar droplet is transported to a separation region containing a substantially non-polar solvent, where non-polar impurities may be extrac...
|
|
WO/2010/076811A2 |
The present invention relates to an efficient and cost-effective process for the preparation of 6- methylenandrost-1,4-diene-3,17-dione (exemestane) by dehydrogenation of 6-methylenandrost-4- ene-3,17-dione using an dehydrogenating agent...
|
|
WO/2010/043404A1 |
The invention relates to a compound of formula (1) wherein R1 represents hydrogen or an acetyl group and R2 represents a methyl, acetyl, or benzyl group, to its preparation, and to its use in the preparation of fulvestrant.
|
|
WO/2010/043506A1 |
Method for preparing 2-alkoxy and 2-aryloxyestrogen compounds, and the intermediate compounds prepared during the use of this method, which intermediate compounds are useful intermediates in the preparation of certain physiologically act...
|
|
WO/2009/135449A1 |
The invention relates to novel ligands of the estrogen receptors α and β of general formula (II), which are useful as active substance of pharmaceuticals, for example pharmaceutical compositions useful for hormone replacement therapy, ...
|
